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Abstract: This review describes strategies for the delivery of therapeutic radionuclides to tumor 
sites. Therapeutic approaches are summarized in terms of tumor location in the body, and tumor 
morphology. These determine the radionuclides of choice for suggested targeting ligands, and 
the type of delivery carriers. This review is not exhaustive in examples of radionuclide carriers 
for targeted cancer therapy. Our purpose is two-fold: to give an integrated picture of the general 
strategies and molecular constructs currently explored for the delivery of therapeutic radionu-
clides, and to identify challenges that need to be addressed. Internal radiotherapies for targeting 
of cancer are at a very exciting and creative stage. It is expected that the current emphasis on 
multidisciplinary approaches for exploring such therapeutic directions should enable internal 
radiotherapy to reach its full potential.
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The drug
In internal radionuclide therapy, as opposed to external beam therapy, the radiations 
of interest are primarily particle emissions (alpha-, beta-particles, and Auger electrons; 
Table 1; see Kassis and Adelstein 2005), that aim on the destruction of the nuclear 
DNA strands by radiation-induced ionizations, excitations, chemical transmutations and 
local charge effects (Nunez et al 1995). During recoil, the ionizing radiation produces 
tracks along which energy is transferred to the surroundings. Linear energy transfer 
(LET) describes the transferred energy per distance traveled by the emitted particles. 
Alpha particles have high LET and produce densely ionizing tracks with highly lethal 
effects. Beta particle emitters, due to lower LET, produce sparsely ionizing tracks 
with lower killing efﬁ  cacy. Beta particles have the longest range in tissue followed 
by alpha particles and Auger electrons. The range of Auger cascade electrons are just 
of the order of a few nanometers, essentially creating a very localized irradiated area 
(sphere) around the decay site of the parent radionuclide (Zaidi and Sgouros 2003). The 
range of these emitted particles in tissue is a great determinant of the size of tumors to 
be potentially treated, and affects other considerations regarding the type of targeting 
ligand and delivery carrier for the parent radionuclide.
Speciﬁ  cally, alpha particles are positively charged monoenergetic helium nuclei 
with the highest energy among particle emissions ranging from 5 to 9 MeV. Alpha 
particles are characterized by LET values of the order of 80 keV/µm along the straight 
line tracks they travel with rate of energy deposition that increases approximately to 
300 keV/µm at the end of the track. Their range in tissue varies between 5 and 10 cell 
diameters (40 to 100 µm) depending on their energy (Kassis and Adelstein 2005). This 
is consistent with the dimensions of micrometastatic disease, allowing for localized 
irradiation of target cells with minimal toxicity on the surrounding normal cells. 
Alphas are particularly effective in cell killing (McDevitt et al 2001): cell survival 
studies have shown that alpha particle induced killing is independent of oxygenation 
state or cell cycle phase during irradiation, and that as few as 1–3 tracks across the International Journal of Nanomedicine 2008:3(2) 182
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nucleus may result in cell death (Humm 1987; Macklis et al 
1988; Humm and Chin 1993; Couturier et al 2005) causing 
single- and double-stranded DNA breaks. Studies on survival 
of normal human epithelial cells suggest that alpha particle 
traversals in the cytoplasm or tangential to the cell nucleus do 
not affect cell survival (Søyland and Hassfjell 2000). These 
studies propose the signiﬁ  cance of the alpha particle traversed 
path length in the cell nuclei rather than the number of alpha 
particle traversals of cell nuclei. Consequently, internaliza-
tion of alpha particle emitters by cancer cells increases the 
chance to kill: alpha particles originating on the cell surface 
have only an estimated 30% probability of traversing the cell 
nucleus (Nikula et al 1999).
Beta particles are negatively charged electrons and their 
range in tissue is of the order of a centimeter that is compa-
rable with larger size tumors. Beta particles have energies 
ranging from 0.05 to 2.3 MeV with LET of the order of 
0.2 keV/µm (Table 1). Consequently, disregarding other 
parameters such as tumor penetration proﬁ  les of radionuclide 
carriers, higher radionuclide concentrations of beta emitters 
compared to alpha emitters are required for comparable cell 
kill (Zaidi and Sgouros 2003). However, the long range of 
beta particles results in a “cross ﬁ  re” effect. This effect is due 
to the long beta particles’ path that crosses multiple individual 
cells. The cross ﬁ  re effect decreases the need to target each 
cancer cell with a radionuclide emitter. Cell survival studies 
show that cells are more sensitive to beta radiation when they 
are arrested in the G2 phase, and are in a good oxygenated 
state. The presence of oxygen upon beta particle irradiation 
generates free radical species that are particularly harmful to 
the nuclear DNA. Both the rate of beta particle disintegra-
tion (half-life) and number of beta emitters (radioactivity) 
at the target site inﬂ  uence the killing efﬁ  cacy by competing 
against the enzymatic repair of the irradiated DNA strands 
(Zaidi and Sgouros 2003).
Auger electrons are low energy atomic orbital electrons 
emitted after electron capture (Kassis et al 1987; Kassis 
2004). During nuclear recoil they produce an array of reac-
tive radicals similar to those formed by alpha particle tracks. 
Because of the nanometer range tracks, the precise subcellular 
localization of Auger emitters can dramatically affect their 
killing efﬁ  cacy. Nuclear localization results in signiﬁ  cant 
enhancement of killing compared to localization at the cell 
surface (Faraggi et al 1994), making the subcellular accumula-
tion sites of Auger emitters of paramount importance on their 
killing efﬁ  cacy (Boswell and Brechbiel 2005).
Tumor response to particle radiation depends on several 
parameters including the absorbed dose, the dose rate, the 
tumor penetration proﬁ  le of radionuclides, the intracellular 
localization proﬁ  les of radionuclides of shorter range, and 
the tumor radiosensitivity.
Calculation of the absorbed dose (D) is necessary to 
quantitatively correlate tumor response to a particular 
radiotherapeutic modality and to project on the potential 
effect of other radiotherapeutic modalities or administration 
strategies. In simple terms, the absorbed dose from a target 
site is deﬁ  ned as the energy (E) absorbed by a particular 
mass of tissue, normalized by the tissue mass (M): D = E/M 
(Sgouros 2005). The absorbed energy is deﬁ  ned as a function 
of three parameters: the number of disintegrations within 
the particular volume of interest (δ), the energy emitted per 
disintegration (ε), and the fraction of emitted energy that 
is absorbed by the particular volume of interest (the target 
mass) (f): E = δ × ε × f. For the relatively long range beta 
emitters, the dose evaluation at a target site includes not only 
the energy emitted by radionuclides localized within the 
target volume, but also the energy emitted by radionuclides 
accumulated in neighboring organs or areas whose emissions 
cross along their path the target volume of interest (Kolbert 
et al 2003). In other words, the calculated total absorbed 
dose is the sum of the dose contributions from all regions 
containing radionuclides that act as secondary sources. The 
adsorbed dose due to photon emissions is usually calculated 
separately and added to the dose due to alpha or beta particles. 
For alpha particle emitters such cross organ absorbed doses 
may be of no signiﬁ  cance due to their short recoil distances. 
At the micron-scale and at distances comparable to a few 
cells, microdosimetric evaluations are used to evaluate dose 
or ‘hits’ acquired by cancer cells within micrometastatic 
clusters (Palm et al 2002).
Evaluation of the rate of clearance and rate of uptake at 
the target site rather than only the total accumulation of a 
radiopharmaceutical at key body sites (bone marrow, liver, 
spleen etc) can provide direct information to mathematical 
modeling for estimation of useful quantities in dosimetry 
such as antigen density (for radioimmunotherapy), tumor 
burden and antigen availability (Kolbert et al 2001).
Table 1 Physical characteristics of therapeutic radionuclides
 Particles  Energy  Emin–Emax Range
β  Electrons  Medium to high*  0.2–12 mm
   (0.05–2.3  MeV)
α  Helium nuclei  High** 5–9 MeV  40–100 µm
EC/IC  Auger electrons  Very low**  Several nm
   (eV–keV)
Abbreviations: EC, electron capture; IC, internal conversion.
Notes: *average values; **monoenergetic.International Journal of Nanomedicine 2008:3(2) 183
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The apparent lethal efﬁ  cacy of the calculated self-dose 
and cross-dose may also be inﬂ  uenced by the bystander 
effect. This effect describes the enhanced killing of cells by 
radiation and even of cells that have not been accessed by the 
radionuclides. It is believed to be a biological effect that has 
been shown to be proportional to the dose that is delivered to 
the neighboring targeted cells, and has been primarily studied 
and veriﬁ  ed in vitro for alpha particle-, beta particle- and 
Auger electron-emitters. Depending on the radiation’s LET, 
this effect has been suggested to be driven by gap junction 
intracellular communications or by secretion from irradiated 
cells of cytokines and free radicals. These secreted compounds 
are taken up by non-irradiated cells that, in turn, respond with 
reduced survival (Snyder 2004). Recently, evidence for the 
bystander effect of Auger electron-emitters in vivo was also 
reported (Xu et al 2002). It is possible that for certain cases 
omission to account for the bystander effect in the dose deter-
mination could interfere with the correct evaluation of the dose 
effect. This is because of the way the dose is traditionally 
determined leading to underestimation of the radiobiological 
effect (Hei et al 2004; Kassis 2004). Currently, the molecular 
and physical mechanism(s) that describe the bystander effect 
are not fully understood. Elucidation of these mechanisms 
should provide the tools to mathematically incorporate their 
effect on dose estimation (Sgouros et al 2007).
Depending on the radiosensitivity of the target site, 
radiosensitizers for beta-particle therapy are also employed 
to improve killing efﬁ  cacy. Major design properties of an 
ideal radiosensitizer and its delivery vehicle include: the 
appropriate timing of the radiosensitizer’s administration 
and its presence at the tumor microenvironment relative to 
the therapeutic radiation, the radiosensitizer’s selective tumor 
accumulation and its adequate tumor localization and reten-
tion. Minimal toxicity and minimal enhancement of radia-
tion toxicity at normal organ sites are major considerations 
(for a review see Kvols 2005). Compounds currently in use 
include molecules that either target DNA (thymidilate syn-
thase inhibitors or platinum analogues), or aim at non-DNA 
targets. p53-mediated radiosensitization was also reported 
using folate-targeting liposomes for wtp53 transfection (Xu 
et al 2001). Examples of the non-DNA targeting category 
include compounds for targeting the epidermal growth factor 
receptor (EGFR), inhibitors of the Ras function, prostaglandin 
inhibitors or compounds that target the tumor neovasculature 
inhibiting angiogenesis and tumor nutrient- and oxygen-
supply. Contrary to beta particles, complete understanding 
of potential radiosensitization mechanisms towards alpha 
particles requires further studies (Supiot et al 2005, 2007).
When radionuclide delivery carriers are designed to 
speciﬁ  cally and directly target cancer cells (or endothelial 
cells of the tumor neovasculature), several criteria need to 
be evaluated regarding the molecular targets, including their 
expression by cancer cells relative to non-targeted cells 
and their relationship to the cell cycle, their surface density 
and their homogeneity on the cell surface. Several types of 
molecular targets used in targeted internal radiotherapy will 
be presented throughout the present review. Characteristic 
types include regulatory peptide receptors like the somatosta-
tin receptors for peptide receptor radiation therapy (PRRT) 
(Reubi et al 2005), EGFR (Hynes and Lane 2005; Normanno 
et al 2006), antiangiogenic molecular targets (vascular endo-
thelial growth factor receptors [VEGFR]) (Alessi et al 2004), 
integrins in antivascular therapies, and other novel targets 
under examination (Britz-Cunningham and Adelstein 2003). 
Correspondingly, the choice of the targeting ligand ideally 
is based on its binding speciﬁ  city to the chosen molecular 
targets and stability in vivo, the target afﬁ  nity and stability of 
the ligand-labeled carriers, and their resistance to degradation 
due to radiation. Stably radiolabeled constructs are crucial. 
For extensive discussions on radiolabeling strategies the 
readers are referred to reviews speciﬁ  c to the subject (Adam 
and Wilbur 2005; Brechbiel 2007).
The carriers
The types of radionuclide carriers reviewed here are catego-
rized based on the disease topology and/or tumor morphology 
and not based on the type of construct (for example lipo-
some- or polymer- or antibody-based). The rationale for 
this approach is to better describe and group the particular 
characteristics of the targeted disease that accordingly inﬂ  u-
ence the design and engineering of delivery carriers.
Metastatic cancer can exist on the same host at different 
stages simultaneously: ranging from single cancer cells or 
micrometastatic tumors to solid tumors. Micrometastases 
refer to small avascular cancer cell clusters. By solid tumors 
larger vascularized multicellular clusters are implied. To 
result in high tumor absorbed doses with relative low normal 
organ accumulation, a variety of designs for targeting carriers 
combined with different radionuclides are proposed. This 
variety emerges from the numerous variables describing each 
case. Such variables include the type (cancer biology) of 
cancer cells that constitute the tumors that would determine 
for example the relevant biomolecular markers, the tumor’s 
anatomic location in the body (topology), the shape and size 
of individual tumors (morphology), the presence or not of 
direct access routes to tumors such as vasculature or direct International Journal of Nanomedicine 2008:3(2) 184
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administration in the space where they may be conﬁ  ned 
(blood or the peritoneal cavity), and others. Independently 
of the type (molecular type, and size) of the delivery car-
rier, stability of radionuclide conjugates is of paramount 
importance. Released radionuclides are free to distribute 
throughout the body and potentially accumulate at normal 
organs increasing toxicity.
In vascularized tumors, the so called “active” targeting 
of drug carriers is directed by specialized targeting ligands 
that aim at the molecular targets located on the surface of 
either the endothelial cells of tumor’s neovasculature or of 
the cancer cells that constitute the tumors. On the contrary, 
“passive” delivery of drug carriers to vascularized tumors 
denotes the extravasation from the blood stream into the 
tumor interstitium, and the preferential retention by tumors 
of nanometer-sized drug carriers compared with smaller com-
pounds. The Enhanced Permeability and Retention (EPR) 
effect that describes this mechanism is due to a combination 
of the tumor leaky neovasculature (Hobbs et al 1998; Jain 
et al 2002), the malfunctioning lymphatics, and the high 
interstitial pressures, and has been veriﬁ  ed experimentally 
by several groups (Hobbs et al 1998; Noguchi et al 1998). 
Nanometer sized carriers or macromolecules exhibiting 
enhanced retention by vascularized tumors are ideal for 
selective tumor accumulation (Noguchi et al 1998; Maeda 
et al 2000). In xenografts of human and murine tumors, the 
vascular reported pore cut off sizes can range from 200 nm 
to 1.2 µm (Hobbs et al 1998). And because passive tumor 
accumulation is a random event, for tumor accretion to 
become clinically compelling, blood circulation of carriers 
needs to be extensively sustained so as to increase the prob-
ability that the carrier will encounter the tumor. Extensive 
increase of the drug carriers’ circulation times with impres-
sive improvement of their biodistributions has been achieved 
by grafting polyethylene glycol polymers (PEGylation) on 
proteins, macromolecules and supramolecular drug carriers. 
It is believed that PEG acts as a steric barrier and interferes 
in the interactions of the carriers with serum proteins, cells of 
the immune- and reticuloendothelial- systems, and with other 
carriers (Lasic and Martin 1995; Allen et al 2002; Auguste 
et al 2003; Gabizon et al 2003; Sofou 2007). In internal 
radionuclide therapy the physical half-life of the delivered 
therapeutic radionuclides can be used as a free parameter to 
optimize the tumor delivered dose with respect to normal 
organ irradiation.
In micrometastatic disease, direct routes of administration 
at the cancer cells’ microenvironment are required to present 
the carrier and targeting moiety in the close vicinity of the 
tumor. Adsorption and internalization of radionuclide carriers 
by cancer cells that constitute the micrometastatic tumors, 
as well as their diffusion through the micrometastasis’ 
interstitial space and their penetration towards the micro-
metastatic core are characteristics that depend on several 
interfacial events. These include the binding strength of 
targeting ligands to cell surface receptors, potential non-
speciﬁ  c attractive interactions between the cell surface 
and the radionuclide carrier surface, and the size of the 
radionuclide carriers (Allen 2002; Emfietzoglou et al 
2005). Alpha- or Auger- emitters, due to their short range 
in tissues, would be more appropriate for effective killing 
of circulating single cancer cells with minimal irradiation 
of the blood vessels.
In all of the above cases, however, a major limitation 
in the therapy of cancer using internal radiotherapy still 
remains the dose-limiting toxicity. This is due to the rela-
tively signiﬁ  cant accumulation of radionuclide carriers in 
vital organs compared to target sites. It is the toxicity that 
prohibits administration of higher doses that could reach 
lethal absorbed levels at the tumor sites. Approaches to 
address this challenge include: direct single-step targeting 
using delivery carriers that result in improved biodistribu-
tions, strategies to stop angiogenesis without affecting 
normal tissues, direct selective targeting and destruction of 
neovasculature, “normalization” of the tumor neovasculature 
to enhance penetration of the drug into the tumor hetero-
geneous interstitial space, tumor accumulation of inactive 
prodrugs and localized “meta-activation” after localization 
at the tumor, direct targeting of easily accessible cancer cells, 
multi-step targeting to dissociate radiotoxicity from carrier-
induced toxicity, and others. Examples of these approaches 
are discussed below.
Single-step tumor accumulation
Here we report on radionuclide carriers without tumor-
speciﬁ  c ligands on their surface. These carriers are designed 
to either passively accumulate within the tumor interstitial 
space following extravasation from circulation in the blood 
stream, or to become physically entrapped into the fenes-
trations of the diseased tissue such as the liver. Magnetic 
radionuclide carriers that are “magnetically targeted” are 
also included in this section.
For vascularized tumors, passive accumulation within the 
tumor interstitial space is primarily inﬂ  uenced by the size and 
circulation time of the nanometer sized carriers. Liposomes 
with encapsulated radionuclides have been extensively 
studied (Hwang et al 1982; Henriksen et al 2004b; Sofou International Journal of Nanomedicine 2008:3(2) 185
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et al 2004b). Liposomes are closed shell structures deﬁ  ned by 
one or more bilayer membranes that enclose an aqueous inte-
rior. The membranes consist of amphiphilic phospholipids 
(double-tailed, single-headed molecules) that self-assemble 
in water. Phospholipid bilayer membranes have a thickness 
of about 4 nm, and liposomes may entrap thousands of water 
soluble molecules in their internal aqueous compartment 
(Lasic 1993). The advantage of liposome-based carriers, apart 
from altering the biodistributions of the radiopharmaceutical, 
is their high drug-to-carrier ratios. High encapsulation efﬁ  -
ciencies of radionuclides by liposomes are achievable. Active 
loading protocols on preformed liposomes have been reported 
in the literature (Hwang et al 1982; Henriksen et al 2004a). 
Due to the current trend in liposome research for biomedi-
cal applications, towards using higher Tg lipid membranes, 
understanding the mechanisms for high radionuclide entrap-
ment efﬁ  ciencies is of great importance. Liver and spleen are 
common accumulation sites for liposomes. Therefore, for 
radionuclide delivery to solid tumors residing in these organs, 
passive accumulation of radiolabeled liposomes could be a 
logical choice. Alternatively, pretreatment with non radioac-
tive liposomes may saturate the hepatic macrophages result-
ing in lower liver uptake of the subsequently administered 
radiolabeled liposomes (Jonasdottir et al 2006).
Dextrans loaded with radionuclides have also been 
extensively studied for passive accumulation at the sites of 
vascularized tumors. Dextrans are branched polysaccharides 
composed of glucose molecules joined into chains of varying 
lengths. They have been in clinical use for several decades 
mainly to decrease vascular thrombosis. Similarly to lipo-
somes, dextran’s size that is of a few nm’s determines their 
localization in the body that is commonly at the liver and 
spleen. Extensive radiolabeling of dextrans and stable reten-
tion of radionuclides is critical for the effectively delivered 
tumor dose and the potential toxicity sites in vivo. Stable 
radiolabeling of dextrans with the beta particle emitter Rhe-
nium-188 (t1/2 = 16.9 h, Emax = 2.11 MeV, maximum range 
of 11 mm in soft tissue) was studied by Du and colleagues 
(2000). It is suggested by the authors that 188Re is particularly 
useful because it also emits gamma photons of 155 keV that 
enable monitoring of uptake and dosimetry calculations. 
However, stability of the rhenium radiocomplexes has been 
reported to be an issue in vitro owed to rhenium’s reoxida-
tion and transchelation. Du and colleagues (2000) modiﬁ  ed 
dextran’s surface by cysteine and used the free thiols for 
radiolabeling with 188Re-gluconate as transchelator. This 
approach exhibited 60%–70% labeling efﬁ  ciency. In physi-
ological conditions–5% human serum albumin in 0.9% saline 
solution at 37 °C – the radiolabeled dextrans released less 
than 15% of conjugated radioactivity for 24 hours in the 
presence of ascorbic acid under a nitrogen atmosphere.
In a different approach for passive accumulation of 
radionuclide carriers at vascularized hepatic tumors, hepatic 
arterial injection of micrometer sized particles has been 
used. In this approach, particles loaded with radionuclides 
are administered for hepatic embolization against primary 
or metastatic liver tumors. Locoregional administration into 
the hepatic artery results in the majority of injected activity 
to remain within the liver that provides almost exclusively 
the blood supply to hepatic metastases. Fortunately, normal 
liver tissue receives only 30% of its blood supply from the 
hepatic artery. Materials used for such microspheres include 
ceramics, polymers, resins or glass (Mantravadi et al 1982; 
Lin et al 1984). Increase of the tumor-to-liver ratio of 
absorbed activities beyond unity is the major requirement 
for minimizing toxicity at the liver parenchymal cells. The 
treatment efﬁ  cacy seems to depend strongly on the vascu-
larity of the hepatic malignancies (Mantravadi et al 1982), 
and it was reported that micrometer sized spheres may be 
too large to be dispersed into the hepatic tumor interstitium. 
Use of smaller size microspheres has been shown to be more 
effective at least in rats (Haefeli et al 1999). Reported chal-
lenges of this approach include heterogeneous microsphere 
distribution with high accumulation near the periphery of 
tumor vasculature and less localization at the tumor center, as 
well as clustering of deposited microspheres (Campbell et al 
2000). In addition, microspheres can potentially be released 
from the liver. In such cases, they commonly accumulate in 
the lungs. Microspheres bearing beta particle emitting radio-
nuclides, mainly 90Y (t1/2 = 2.67 days, Emax = 2.28 MeV), 186Re 
(t1/2 = 3.78 days, Emax = 1.077 keV, maximum range of 6 mm 
in soft tissue) and 188Re have been reported. Rhenium has 
the advantages of shorter required neutron activation times 
compared to 90Y, and the ability to allow for imaging. This 
is due to the gamma emissions which constitute 9.5% for 
186Re and 15.0% for 188Re emissions with energies 137 and 
155 keV, respectively. Clinical trials with 90Y-microspheres 
show encouraging results both for primary and metastatic 
liver tumors (Houle et al 1989; Salem et al 2002; Murthy 
et al 2005). Microspheres contain rhenium metal or 89Y 
without chelation. Generally, small amounts of radioactivity 
are reported to leak from microspheres in vitro. Rhenium 
compounds released from glass microspheres have been 
reported to accumulate in the thyroid. For 90Y, bone marrow 
accumulation has been reported that could lead to myelosup-
pression (Haefeli et al 1999).International Journal of Nanomedicine 2008:3(2) 186
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Magnetic targeting has also been explored as an alternative 
strategy to enhance tumor accumulation with the objective to 
minimize systemic toxicity. Magnetic microspheres contain-
ing therapeutic radionuclides were used in this approach, and 
enhancement of localization of the delivery carriers at the 
tumors is achieved by using external magnetic ﬁ  elds. Hafaeli 
and colleagues (1995) synthesized micron-size poly(lactic 
acid) spheres with incorporated magnetite and the beta par-
ticle emitter 90Y, and demonstrated enhanced killing efﬁ  cacy 
of neuroblastoma cells when a magnet was used to direct the 
microspheres closer to cells in vitro. In vivo studies showed 
high tumor accumulation by magnetic poly(lactic acid) radio-
micropheres when directed towards a subcutaneous tumor by 
an external ﬁ  xed magnet after intraperitoneal administration. 
Stable radiolabeling of magnetic nanoparticles with 188Re 
is reported (Haefeli et al 2001). In a different approach, 
Chunfu and colleagues (2004) developed 200 nm particles 
composed of magnetite nanoparticles covered with human 
serum albumin and labeled with 188Re via its sulfur surface 
atoms. These nanoparticles showed stable radionuclide reten-
tion in albumin solution for up to 72 hours.
After extravasation of radionuclide carriers into solid 
tumors, diffusion is the main transport mechanism that 
governs their penetration and dissemination throughout 
the tumor’s interstitial space. Tumor interstitial diffusion 
is hindered by the extracellular matrix (ECM) compris-
ing primarily collagen and glycosaminoglycans (such as 
hyaluronan). The effect of these biomacromolecules on the 
transport characteristics of antibodies and liposomes has 
been extensively studied (Netti et al 2000; Znati et al 2003). 
X-ray radiation may further hinter the interstitial diffusion. 
In particular, interstitial diffusion may be further decreased 
due to the tumor levels of collagen type I within the tumor 
interstitium that seem to increase due to irradiation. It has 
been suggested that collagen binds and stabilizes the glycos-
aminoglycan component of the ECM resulting in increased 
resistance to the transport of macromolecules (Netti et al 
2000). In vivo, decreased diffusion that was attributed to 
the increased levels of collagen type I was measured after 
external irradiation in subcutaneous implants of human colon 
(Znati et al 2003).
However, extravasation of the circulating drug carrier into 
the tumor interstitium depends on the endothelial wall perme-
ability, and it precedes the carrier’s diffusion and penetra-
tion into the tumor’s core space. Kalofonos and colleagues 
(Kalofonos et al 1990) showed that vascular permeability of 
the tumor endothelium in human colon tumor xenografts sig-
niﬁ  cantly increases soon after exposure to X-ray irradiation. 
However, this lasts only for short time periods. Therefore, 
the same type of radiation can differently affect the accu-
mulation of radionuclide carriers to vascularized tumors by 
transiently increasing the endothelial wall permeability and 
by enhancing ECM’s structural integrity. Timing of irradia-
tion with respect to drug carrier administration was shown 
to play an important role in the therapeutic effects of lipo-
somally encapsulated doxorubicin on human osteosarcoma 
xenografts when combined with external radiation. In this 
study, improved intratumoral distribution and tumor uptake 
was shown that can be achieved with appropriate timing 
(Davies et al 2004).
Other approaches to improve penetration of macromo-
lecular delivery carriers in vascularized solid tumors include 
administration of enzymes that can degrade the ECM. 
Towards this goal, collagenase (Eikenes et al 2004) and 
hyaluronidase (Eikenes et al 2005) were evaluated in vivo on 
human osteosarcoma xenografts. In particular, before admin-
istration of an osteosarcoma speciﬁ  c monoclonal antibody, 
collagenase was administered intravenously. Although the 
particular enzyme is not clinically relevant because it may 
favor metastasis, a twofold increase in the tumor uptake of 
the osteosarcoma speciﬁ  c antibody was observed. In addition, 
the antibody exhibited improved penetration in the tumor. 
Using larger drug carriers, Eikenes and colleagues (Eikenes 
et al 2005) showed signiﬁ  cant enhancement in tumor accu-
mulation of intravenously administered liposomal drug car-
riers. This was achieved by administering intratumorally, 
preceding the administration of liposomes, the ECM enzyme 
hyaluronidase that degrades the extracellular tumor matrix. 
The adjuvant use of hyaluronidase has already been used in 
phase I and II trials to improve prevention of tumor regrowth 
when administered with chemotherapy. Surprisingly, intra-
venous administration of the enzyme was not found to be 
toxic to normal tissues (Bruera et al 1999). Such strategies 
of EMC pretreatment could, in principle, be applied to other 
types of macromolecular and nanometer sized delivery carri-
ers in internal radiotherapy for improvement of the carrier’s 
distribution within solid tumors.
In solid tumors, the irregular tumor vasculature may lead 
to heterogeneous distributions of the radionuclide carriers 
resulting in variable microdosimetric distributions. The 
signiﬁ  cance of this effect to the delivered dose depends on 
the tumor size relative to the range of the emitted particles 
in tissue. Nonspeciﬁ  c interactions between the delivery car-
riers and cancer cells in tumor spheroids that may contribute 
to these irregularities were studied for liposomes and the 
role of electrostatics and steric repulsion (PEGylation) was International Journal of Nanomedicine 2008:3(2) 187
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shown to be signiﬁ  cant (Emﬁ  etzoglou et al 2005). When 
targeting ligands such as antibodies are used, high afﬁ  nities 
for the cell receptors, fast antigen internalization and slow 
diffusion were shown to result in high accumulation only at 
the perivascular regions (Adams et al 2001). A recent theo-
retical study on evaluating the criteria for efﬁ  cient antibody 
penetration into solid tumors and micrometastases suggests 
that because of the “binding site barrier” antibodies could 
possibly be more suitable for targeting micrometastases 
(Thurber et al 2007).
Targeting of tumor vasculature
Receptors overexpressed on the endothelial cells comprising 
the tumor neovasculature are used as targets for therapy and 
diagnosis. Development of vasculature is needed for solid 
tumors to grow beyond 1–2 mm3 in size (Folkman 1990), 
and endothelial vascular cells in malignant state will divide 
as fast as every 7–20 days as opposed to every 20 years when 
in a healthy state (Hobson and Denekamp 1984; Scott and 
Harris 1994). In some cases of solid tumors, direct targeting 
of the neovasculature itself with radionuclides could be more 
attractive and efﬁ  cient than targeting molecular markers on 
the surface of cancer cells that reside within tumors. In the 
latter case, the radionuclide conjugates will have to overcome 
additional barriers related to extravasation and diffusion/ 
penetration within the tumor interstitium.
The therapeutic strategies that involve targeting of the 
tumor neovasculature are categorized as antiangiogenic (or 
angiostatic) and as antivascular (or angiolytic). Antiangio-
genic refers to the prevention of new blood vessel formation 
and includes targeting of growth factor receptors on the vas-
culature endothelial cells. Antivascular refers to damaging 
and killing of tumor cells by cutting the blood ﬂ  ow via the 
neovasculature, so as to deprive the tumor of growth factors 
(Folkman 1971), using as targets other characteristic markers 
such as integrins.
Healthy vasculature is composed of endothelial cells that 
create the walls of the vascular lumen. Endothelial cells are 
surrounded by pericytes and a basement membrane. Pericytes 
interfere with endothelial cell proliferation, microvessel out-
growth, and stabilization of the capillary walls (Sims 1986). 
Angiogenesis is the formation of new vasculature. Tumor 
vessels are abnormal in many respects. They may lack peri-
vascular cells that protect vessels from changes in oxygen and 
hormonal levels, and the vessel wall itself might contain not 
only endothelial cells but also cancer cells resembling more 
of a mosaic. Choosing targeted marker molecules should be 
inﬂ  uenced by this architecture (Carmeliet and Jain 2000).
The rationale for targeting the tumor vasculature is based 
on the observation that without adequate vasculature tumor 
cells are shown to become necrotic or apoptotic (Burrows and 
Thorpe 1993; Brooks et al 1994). However, studies on target-
ing tumor vasculature have shown that by depriving tumors 
of oxygen, tumor cells may transform into hypoxic cells 
and consequently become more resistant to chemotherapy 
and radiation (Bottaro and Liotta 2003). Hypoxic cells can 
activate the production of proteins (hypoxia-inducible factor 
[HIF]) that are involved in VEGF/VEGFR-2 signaling, and 
increase the formation of protease enzymes that degrade the 
basement membrane and the extracellular matrix, thus pro-
moting in this way cell mobility and invasion, and resulting 
in metastasis of cancer cells, and migration of the endothelial 
cells into the tumor interstitial space where they proliferate 
and create new vasculature.
Characteristic molecular targets that have been studied 
and extensively utilized include: the VEGFR, integrins, 
matrix metalloproteases, and other endogenous antiangio-
genic factors. Matrix metalloproteases are neutral endopepti-
dases that can degrade the ECM. They interact with integrins 
and the endothelial growth factors. Matrix metalloproteinase 
inhibitors aim to inhibit the action of these metalloproteases. 
The cell surface proteoglycan NG2 marker of angiogenic 
pericytes (Burg et al 1999) or the oncofetal ﬁ  bronectin that 
resides in the immediate ECM of blood vessels supplying 
malignant sites have also been suggested as alternative and 
very interesting targets (Ruoslathi 2002).
VEGF in particular, and its receptors, are important com-
ponents in the process of angiogenesis. There are six growth 
factors in the VEGF family (the most well-characterized is 
VEGF-A) and three receptors which are transmembrane 
tyrosine kinases predominantly found in endothelial cells. 
VEGF is present in normal tissues and in tumors. As men-
tioned above, activation of the VEGFR-2 is connected to 
enhanced vascular permeability and proliferation of endo-
thelial cells (Rosen 2005), and antibodies against VEGFR-2 
have been explored as inhibitors of angiogenesis (Li et al 
2005). A systematic review of several studies on the com-
bined administration of therapeutics to block proangiogenic 
factors (anti-VEGF) or administration of antiangiogenic 
factors with external radiation has been published by Nieder 
and colleagues (2006). The interaction mechanisms of tumor 
endothelial cells with antiangiogenic factors and ionizing 
radiation is particularly complex. Studies of such systems 
with internally targeted radionuclides whose action is not 
characterized by radioresistance, still needs to be explored 
(Wachsberger et al 2003).International Journal of Nanomedicine 2008:3(2) 188
Sofou
In antivascular strategies, targeting of integrins has 
attracted particular interest. Alpha v beta 3 integrin is 
expressed in newly formed endothelial cells and on endothe-
lial cells of the neovasculature (Ruoslathi 2002). Its function 
is related to cell adhesion, and certain members of the integrin 
family are involved in cancer metastasis and angiogenesis. 
Brieﬂ  y, integrins are bidirectional heterodimeric recep-
tors consisting of one alpha- and one beta-subunit, and are 
activated by the tripeptide sequence Arg-Gly-Asp (RGD) 
(Ruoslathi and Pierschbacher 1986). Upon binding of an 
RGD-type peptide to a resting integrin, a series of signals is 
transduced that causes dissociation of alpha, beta- heterodi-
mers and formation of clustered homooligomers (alpha-, 
and beta-oligomers). This surface nanopatterning creates 
adhesion focal points on the cell surface that is shown to 
lead to strong binding with multivalent ligands (multimeric 
RGD ligands) (Wester and Kessler 2005). When a competi-
tive antibody or molecule bearing the RGD motif disrupts 
the integrin ligand interaction, blocking of formation of 
new blood vessels takes place, which is the basis for some 
antivascular therapeutics.
Janssen and colleagues (2002) studied an 90Y labeled 
RGD-peptide to target the alpha v beta 3 integrin on the 
neovasculature of OVCAR-3 ovarian carcinoma xenografts. 
The study showed that the radiolabeled peptide delays tumor 
growth, but investigation of possible optimization of tumor-
targeting and tumor therapy using dose fractionation did not 
improve the therapeutic efﬁ  cacy of the radiolabeled peptide 
(Janssen et al 2004).
In a different approach, because it is the larger tumors 
that develop neovasculature networks, combination of 
active targeting and passive targeting was studied by Line 
and colleagues (Line et al 2005). For active targeting mul-
tivalent RDG sequences were used that were attached on 
relatively large delivery carriers to also exploit passive 
targeting demonstrated by the EPR effect. In particular, a 
30kDa 99mTc-labeled HPMA copolymer was developed that 
was conjugated to RGD-containing peptides (Koivunen 
et al 1995), and was evaluated in two xenograft models of 
prostate cancer. The studies veriﬁ  ed the additive effect of the 
two targeting mechanisms in tumor uptake, namely active 
and passive, but passive accumulation contributed to a lesser 
extent (Line et al 2005). Mitra and colleagues (Mitra et al 
2006) also studied the antitumor effectiveness of a HPMA 
copolymer conjugated to multivalent RDG sequences and 
loaded with 90Y. Signiﬁ  cant decrease in tumor volume was 
observed with increased apoptosis in treated tumors, and 
with no acute signs of toxicity to normal organs in a SCID 
mouse xenograft model of human prostate carcinoma. A 
combination of short range and long range particle emitters 
such as alpha and beta particles would be an interesting 
approach for such a construct. This suggestion is based on 
the assumption that the emitted alpha particles may have 
stronger killing impact on the endothelial cells, while the 
emitted beta particles are ideal for irradiating the cancer cells 
comprising the solid tumors.
The potential antivascular effect of alpha particle emitters 
has been proposed (Thorpe and Burrows 1995), and studied 
in vitro and in animals (Kennel and Mirzadeh 1998). Only 
recently, efﬁ  cacious results were demonstrated in humans 
(Allen et al 2007). In particular, in a phase I trial of systemic 
melanoma the 9.2.27 monoclocal antibody was radiolabeled 
with Bismuth-213 (t1/2 = 45.59 min) via cDTPA and was 
used to target the core glycoprotein of the melanoma associ-
ated chondroitin sulfate proteoglycan (MCSP). The studies 
showed partial or complete tumor regression in patients that 
was unexpected. This is because the alpha particle therapy 
was not intended for solid tumors but rather for circulating 
micrometastases. However, in the particular cancer, the 
targeted cancer cells are known to express the same MCSP 
antigen as the pericytes in solid tumors. Therefore, it was 
suggested that after extravasation of the radioimmunocon-
structs into the solid tumor and binding to pericytes, the alpha 
particle emitters were localized not far from the vascular 
endothelial cells which they irradiated and killed. The authors 
concluded that the induced endothelial cell death resulted in 
closure of the capillaries and starvation of the solid tumors. 
Further investigation of this approach could result in alterna-
tive uses of alpha particle emitters.
Alternatively, an interesting approach to transiently 
produce vascular “normalization” followed by administra-
tion of chemotherapy or radiation has been proposed by Jain 
(2005). The rationale is based on the hypothesis that although 
antiangiogenic monotherapy causes destruction of the neo-
vasculature, and higher doses should be more effective, high 
antiangiogenic doses may harm the vasculature of normal 
tissues as well, including the cardiovascular, endocrine, and 
nervous systems (Carmeliet and Jain 2000). In addition, 
because the blood supply network within the tumor is het-
erogeneous and interferes with our ability to deliver drugs 
into the tumors, administration of moderate antiangiogenic 
doses will not completely destroy the neovasculature. Also, 
in cases of combination therapies, it may leave the intratu-
moral drug delivery impaired. It is therefore suggested that 
“normalization” of the tumor vasculature should occur ﬁ  rst 
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Radionuclide carriers for targeting of cancer
spatial vascular network within the tumor. In this way, tumor 
neovasculature will become less tortuous. Subsequently, and 
during the functional window where normalization occurs, 
administration of anticancer therapeutics should take place. 
This strategy could result in higher and more homogeneous 
uptake of therapeutics, which should be able to penetrate 
and disseminate deeper into the tumor interstitium and cells. 
Better drug distribution throughout the tumors combined with 
higher tumor oxygenation should increase the tumor killing 
efﬁ  cacy. However, identiﬁ  cation of the appropriate timing 
of each process should not be trivial.
Various ligands towards endothelial molecular targets 
have been developed and tested mainly for imaging of angio-
genesis, but the same ligands can be in principle used for tar-
geting of radionuclides. A systematic review on angiogenesis 
imaging and also on imaging of other aspects of tumor state 
(proliferation, apoptosis, hypoxia, etc) is authored by Britz-
Cunningham and Adelstein (2003). An interesting approach 
for vasculature targeting that has been extensively pursued 
is to ﬁ  rst preactivate the neovasculature so as to increase the 
density of molecular targets on the endothelial cells and then 
to deliver the killing radiation or other therapeutics. This 
approach is reviewed in the following section.
Preactivating
Upregulation of targeting proteins on the endothelial cells 
comprising the tumor’s blood vessels is the aim of radia-
tion-guided drug delivery using external radiation such as 
X-rays. At a second step, ligand-conjugated drug carriers 
are targeted towards the upregulated protein targets of the 
neovasculature.
For antiangiogenic therapies, high tumor-to-normal 
organ ratios can be potentially achieved by inducing over-
expression of targeting proteins on the tumor neovasculature 
when these proteins occur on the luminar surface of the 
endothelium. Characteristic protein examples include the 
intercellular adhesion molecule-1 (ICAM-1), E-selectrin, 
P-selectin (Hallahan et al 2001a), and the β3 integrins 
(Hallahan et al 2001b).
In particular, Hallahan and colleagues (2003) caused 
upregulation of the α2bβ3 receptor of tumor microvascu-
lature using ionizing radiation. As targeting ligand they 
used ﬁ  brinogen - the native ligand of α2bβ3 – or peptide 
fragments of ﬁ  brinogen containing the RGD motif. The 
ligand was conjugated to nanoparticles and other delivery 
carriers such as liposomes which were then administered to 
embolize the activated tumor microvasculatures in vivo in a 
murine melanoma animal model. This approach resulted in 
signiﬁ  cant decrease of the tumor blood ﬂ  ow that signiﬁ  cantly 
delayed tumor growth.
Preferential targeting of irradiated tumors resulting in 
signiﬁ  cant delay of tumor growth was also observed in vas-
cularized B16-F10 melanoma xenografts that were initially 
irradiated by x-rays to increase expression of the alpha v 
beta 3 integrin on the tumor endothelium. They were then 
targeted by liposomes conjugated to RGD sequences with 
encapsulated combretastatin that is an antivascular agent 
already evaluated on clinical trials (Pattillo et al 2005).
The strategy of radiation-guided targeted drug delivery to 
tumor blood cells seems to be promising and has been used 
till now to deliver conventional therapeutic compounds and 
radionuclides for imaging (Hallahan et al 2003). Studies 
on the delivery of therapeutic radionuclides for targeted 
antiangiogenic internal radiotherapy after upregulation of 
the molecular targets by external radiation are expected that 
will soon be reported.
Meta-activating strategies
By the term “meta-activating”, we refer to therapeutic strate-
gies where prodrugs that have been delivered to tumor sites 
are activated in situ by an external stimulus which could 
be neutrons, X-rays, gamma photons, or another source of 
radiation. This type of localized therapy is designed to result 
in minimal toxicities. This would be achievable as long as 
the inactive prodrug form that accumulates at normal organs 
is decomposed and removed from the body with minimal 
side effects.
In internal radionuclide therapy the most common 
example is boron neutron capture therapy (BNCT). In this 
approach, the prodrug is the stable isotope Boron-10 that 
upon irradiation by thermal neutrons, forms the highly ener-
getic particulate species 7Li and 4He (an alpha particle) by 
neutron capture and nuclear ﬁ  ssion, and a 0.48 MeV gamma 
photon is emitted via the neutron capture mechanism. In 
addition, the total dose in tissue has two more components: 
the gamma ray of energy 2.22 MeV that is released due to 
thermal neutron capture by hydrogen atoms in tissue, and a 
proton due to reaction of thermal neutrons with the tissue 
nitrogen (Ryan and Poston 2005). The dose due to interac-
tion of thermal neutrons with tissues is not insigniﬁ  cant, 
but lower than the dose due to alpha particles emitted from 
irradiated 10B.
Because the recoil range of the emitted lithium and helium 
particles in tissue is 5 and 7 µm, respectively, which is com-
parable to the size of a single cell, the cellular internalization 
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to the cell nucleus is a major determinant of the therapeutic 
efﬁ  cacy for this approach. The chemical form of the boron 
isotope is of great importance for BNCT because it may 
interfere with boron’s subcellular localization (cytoplasmic, 
exoplasmic, or endonuclear). pH-sensitive drug carriers that 
become endocytosed and release their contents into the cyto-
plasm, such as liposomes, could provide a potential answer 
to the subcellular localization issue. In order to achieve a 
lethal dose per cancer cell, 109 Boron-10 atoms (Javid et al 
1952; Tolpin et al 1975; Hartman and Carlsson 1994) need 
to be delivered per target cell. An informative review by 
Zamenhof (1997) analyzes the issues related to the short 
recoil of emitted particles in terms of boron microdosimetric 
evaluations.
Using monoclonal antibodies serving both as the target-
ing ligand and the delivery carrier would be challenging 
for this type of therapy. This is because heavy boron loads 
are required for adequate delivered doses to cancer cells, 
and antibody conjugation generally results in relatively 
low prodrug-to-antibody ratios. Extended conjugation of 
antibodies for boron loading would not be a solution as 
it could interfere with the antibody’s immunoreactivity 
potentially resulting in lower tumor accumulation and 
higher liver uptake (Paxton et al 1992). To address these 
issues, bispeciﬁ  c antibodies were successfully designed. 
These antibodies bind to tumor speciﬁ  c antigens and also 
recognize a hapten included on the boron-containing car-
borane constructs (Pak et al 1995). For BNCT, other types 
of carriers, such as dendrimers, and liposomes with high 
prodrug-to-carrier ratios are also studied, both as targeted 
and as passive delivery carriers. A disadvantage for neutron 
capture therapy is the availability since thermal neutron 
beams originate from nuclear reactors. However, epithermal 
neutron beams with energy ranging from 0.5 eV to 1 keV 
can be produced by charged-particle accelerators that can 
be installed in an urban environment. Epithermal neutrons 
loose energy while traversing the tissue and become captur-
able when they reach the boron targets.
Dendrimer-based delivery
Dendrimers are spherical monodispersed multivalent poly-
mers with high degrees of branching. They have been 
extensively studied as carriers for the delivery of chemothera-
peutics, prodrugs, radionuclides and other molecules for ther-
apy and imaging of cancer (Gillies and Frechet 2005), although 
their toxicity is still unclear (Duncan and Izzo 2005).
Accumulation of boronated polyamidoamine (PAMAM) 
dendrimers is signiﬁ  cant at the liver and spleen, and seems 
to be directly related to the dendrimer generation. This is 
the major challenge using these constructs. In particular, 
intraperitoneal administration of second and fourth genera-
tion of boronated dendrimers with reactive terminal amino 
groups labeled with tumor speciﬁ  c antibodies were evaluated 
in tumor-free mice and in mice bearing subcutaneous B16 
murine melanoma implants (Barth et al 1994). The reported 
liver uptake was higher than the accumulation at the tumors 
at all time points ranging from one to ﬁ  ve days. Surface modi-
ﬁ  cation of dendrimers to reduce liver uptake will be critical 
for the successful implementation of these constructs.
In another study, PEGylation was used to increase 
the blood circulation times of third generation boronated 
PAMAM dendrimers. In addition, dendrimers were labeled 
with folic acid to improve their targeting and accumulation 
to tumor cells overexpressing folate receptors (Shukla et al 
2003). However, although in vitro studies showed recep-
tor-mediated uptake, the biodistributions in mice bearing 
subcutaneous folate receptor (+) murine 24JK-FBP sarco-
mas conﬁ  rmed the complexity of using denrimers. Two 
PEGylated forms of dendrimers were evaluated: the ﬁ  rst 
type contained approximately one PEG chain of 2000 MW 
per dendrimer with the folic acid attached to its distal end. 
The second type contained one PEG chain of 2000MW and 
in addition a shorter PEG chain of 800 MW with the folic 
acid attached to its distal end. In vivo studies showed that 
PEGylation reduced the renal uptake that was very high for 
non-PEGylated conjugates. Hepatic uptake was reduced with 
diPEGylation. However, in the later case, although the tumor 
uptake was signiﬁ  cant (6.0% ID/g tumor), the accumulation 
at the liver, kidney, and spleen was 6.5, 10.5, and 4 times 
higher than the tumor uptake 6 hours after intraperitoneal 
administration of the targeted boronated dendrimers. The 
degree and type of PEGylation was shown to play a critical 
role on the pharmacokinetics of these systems. The high 
values of normal organ uptake suggest that further optimiza-
tion will be required for targeted PEGylated dendrimers to 
become applicable in vivo.
To bypass the challenge of the circulation times of den-
drimers that are shorter than those required for signiﬁ  cant 
accumulation into solid tumors (Malik et al 2000), more 
accessible molecular targets such as those found on the 
tumor endothelial walls have been proposed for systemically 
administered boronated dendrimers. Fifth-generation boro-
nated PAMAM dendrimers (Baker et al 2005) conjugated to 
a vascular endothelial growth factor (VEGF) targeting the 
VEGF-2 receptor of the tumor neovasculature were evalu-
ated in a 4T1 breast carcinoma mouse model. The in vivo International Journal of Nanomedicine 2008:3(2) 191
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studies showed selective accumulation at the areas of active 
angiogenesis consistent with a VEGFR-2-mediated binding 
mechanism that was veriﬁ  ed in vitro. Application of boro-
nated dendrimers with high prodrug-to-carrier loads to target 
easily assessable disease may be an appropriate ﬁ  t for these 
constructs. The localization of these boronated bioconjugates 
in endothelial cells, and how their subcellular distributions 
interfere with their therapeutic efﬁ  cacy is left to be explored. 
These boronated bioconjugates may provide an effective 
approach for antiangiogenic therapy using BNCT.
Liposome-based delivery
Mostly due to the high encapsulation efﬁ  ciency of water 
soluble compounds, several studies have evaluated the use 
of liposomes in BNCT in vivo.
Liposomes – with and without PEGylation – encapsulating 
different boron-containing species were studied by Feakes and 
colleagues (1994), and were evaluated in vivo on a EMT6 
tumor bearing mouse model. The rationale for using liposomes, 
besides the altered biodistributions and pharmacokinetics, is 
liposomes’ ability to encapsulate and deliver free hydrophilic 
forms of boron to cancer cells. This is of great importance as 
only those boron forms that are released intracellularly and 
react with intracellular proteins could be adequately retained 
by the tumors. If boron retention by tumors is sustained for 
long time periods, then toxicity to normal organs, as is the 
liver, could be minimized. In other words, sustained tumor 
retention would offer the circulating liposomes enough time 
to clear from the blood and other tissues before activation of 
the tumor accumulated prodrug. Feakes and colleagues (1994) 
report for plain non-PEGylated liposomes, sixteen hours after 
intravenous administration, the tumor-to-blood ratio to be 5 
and the boron accumulation at the tumor to be comparable to 
required therapeutic values for BNCT. Similar tumor-to-blood 
ratios have been reported by other groups studying liposomal 
delivery of boronated species (Hawthorne and Shelly 1997). 
For PEGylated liposomes, Feakes and colleagues (1994) report 
that the blood circulation time was further extended and after 
48 hours the tumor-to-blood ratio was evaluated to have the 
lower value of 2.4. In these studies, liposomes exhibited tumor 
uptake and boron retention that were sustained over time. 
However, liver is a common site of liposome accumulation. 
In these studies, it exhibited boron uptake comparable with 
the tumor accumulation values, which, however, were sig-
niﬁ  cantly lower than values obtained with boron-conjugated 
dendrimers as mentioned in the previous paragraphs. To 
appropriately evaluate the therapeutic efﬁ  cacy and toxicity of 
liposome-mediated BNCT, it would be necessary to determine 
the clearance kinetics of liposomes from normal organs and 
to optimize the timing for boron activation relative to tumor 
retention times.
As mentioned above, a key challenge in BNCT is the 
delivery of adequate prodrug concentrations to cause cell kill 
upon activation. To achieve high encapsulated boron contents 
in liposomes both passive loading of boron-containing agents 
and active loading approaches have been explored. Pan and 
colleagues (2002b) developed remote-loading protocols 
of boronated polyamines using a pH-gradient across the 
liposome membranes. They demonstrated higher loading 
efﬁ  ciencies when lower molecular weight boron derivatives 
were used in liposomes encapsulating ammonium sulfate as 
the trapping agent. Liposomes were then targeted to the folate 
receptors of human KB squamous epithelial cancer cells. 
Neither the chemical form of boron nor the mechanism of 
boron loading in liposomes did inﬂ  uence the incracellularly 
accumulated boron that was delivered to cancer cells by 
targeting liposomes. This study concluded that high con-
centrations of boron per cell could be delivered that would 
greatly exceed the required lethal boron amount per cell for 
effective BNCT. To evaluate feasibility in vivo, the reten-
tion times of boron compounds by cancer cells relative to 
liposome circulation times and clearance from normal organs 
should be investigated.
In another study, increased tumor accumulation in mice 
bearing subcutaneous FR (+) M109 murine lung carcinomas 
was detected for folic-acid labeled PEGylated liposomes 
with encapsulated boron compounds following intravenous 
administration. High tumor-to-blood ratio was detected for 
the targeting liposomes until 72 hours post-administration. 
However, the tumor uptake of targeting liposomes was 
comparable to nontargeting liposomes. This result possibly 
resonates with the mechanism of the enhanced tumor perme-
ability and retention that depends primarily on the size of 
the delivery carrier. Both carriers were based on the same 
liposome membrane and size. However, upon extravasation 
into the tumor interstitium, targeting ligands on the liposome 
surface may enhance their cell uptake and internalization 
(Kirpotin et al 2006). Cellular internalization and the subcel-
lular localization of targeting and non-targeting boronated 
liposomes require further investigation to evaluate their thera-
peutic effect (Pan et al 2002a). Promising results regarding 
the delivered prodrug dose per cell have been reported (from 
in vitro studies) with anti-EGFR liposomes with encapsulated 
boron (Kullberg et al 2005). Also, RGD-labeled liposomes 
have also been studied to target the endothelial wall of the 
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Transferin labeled PEGylated liposomes with encapsulated 
boron compounds exhibited tumor suppression and improved 
long-term survival to subcutaneous colon 26 tumors in mice. 
Liposomes were administered intravenously. Seventy-two 
hours after administration, when the tumor-to-blood ratio 
was 6 and the liver accumulation was less than the tumor 
uptake, neutron activation took place (Maruyama et al 2004). 
These liposomes were shown to deliver therapeutic boron 
doses to the tumors. It was suggested that transferin-label-
ing enhances retention of liposomes in the tumors and also 
mediates liposome internalization by cancer cells that consti-
tute the tumors. Internalization and release of encapsulated 
contents would increase the therapeutic efﬁ  cacy by allowing 
boron-conjugates to approach the cell nuclei. Towards the 
enhancement of intracellular release of contents, liposomes 
that can directly fuse with the cell membrane and are com-
posed of the positively charged DOTAP and the zwitterionic 
DOPE (a hexagonal phase lipid) were studied for BNCT 
(Ristori et al 2005). These compositions are already used 
in gene therapy, but they will probably require some addi-
tional degree of stealthness during blood circulation since 
their positive charge could result in nonspeciﬁ  c interactions 
with healthy cells, and in signiﬁ  cant uptake by Kupffer cells 
residing in the liver (Zhang et al 2005).
Other liposome based structures involve boronated 
lipid (Justus et al 2007) or cholesterol (Thirumamagal et al 
2006) derivatives incorporated into the lipid bilayer. These 
approaches do not take advantage of the encapsulated aque-
ous compartment.
Other structures
Other carriers studied for delivery of boron compounds for 
BNCT include cationic acrylamide copolymers. Copolymers 
with variable positive charge and mean size of 10 kDa were 
evaluated for uptake by induced polyps on the luminal side 
of the gut in rats. The cationic monomer content was varied 
and boron uptake by the polyps was shown to be an inverse 
function of the cationic content of the copolymer. This was 
attributed to the thicker and more negative—richer in sialic 
acid—mucus that is due to higher mucin production by colon 
carcinoma cells. The ratios of boron content between the 
polyps and the surrounding normal epithelium ranged from 
6.5 to 1.5 with the higher ratio characterizing the less cationic 
copolymers (Azab et al 2005). The authors of this study 
concluded that for residual disease in the colon, BNCT could 
achieve therapeutic effects with minimal toxicities when 
delivered and targeted by cationic acrylamide copolymers 
that will be administered by microenema.
Single-walled carbon nanotubes (SWCNT) have also 
been studied as carriers of boron for BNCT. Boronated 
SWCNTs were administered intravenously in mice bearing 
EMT6 mammary carcinomas. SWCNTs were dissolved and 
administered in either saline or DMSO solutions. Fast blood 
clearance was detected, and tumor to blood ratio was 3.12 
and 6.13 for saline and DMSO, respectively, 48 hours after 
administration. Both solutions showed stable tumor retention 
over a period of 48 hours with tumor-delivered boron doses 
slightly lower than the therapeutic values. The liver, lung, and 
spleen uptake was lower than tumor uptake; however, kidney 
accumulation was not reported. These promising results need 
to be augmented by elucidation of SWCNTs cell binding and 
subcellular localization (Yinghuai et al 2005).
Easily accessible disease
Easily accessible refers to these types of disease for which 
the drug delivery carriers after administration are in direct 
contact or at the very close vicinity of the targeted cancer 
cells. We will review studies on drug carriers that are admin-
istered intraperitoneally to directly target intraperitoneally 
disseminated metastatic cancer. Radioimmunotherapy (RIT) 
of hematopoietic cancers is also a vast area of research that 
falls within this category. Included also, are approaches to 
decrease the toxicity of these therapies to normal organs.
Peritoneal carcinomatosis
Peritoneal carcinomatosis is common for several metastatic 
gynecological and gastrointestinal cancers. A promising 
approach for the therapy of peritoneally disseminated cancer 
is intraperitoneal administration of therapeutic agents. The 
rationale for intraperitoneal administration is twofold. First, 
for micrometastatic tumors in the peritoneal cavity developed 
vasculature in the peritoneal tumor does not exist (Li et al 
2000). For these particular cases, intravenous administra-
tion of therapeutics will not be the optimal route to target 
intraperitoneal micrometastases.
Second, since intraperitoneal administration provides 
direct access to peritoneally disseminated disease, high 
concentrations of the therapeutic agents could be achieved 
in the peritoneal cavity, before their concentration reaches 
toxic levels in the dose limiting organs (Buijs et al 1998; 
Borchardt et al 2003). Particularly for internal radiotherapy, 
it is conceivable to match the clearance kinetics from the 
peritoneum and the kinetics of normal organ uptake with 
the half-life of the delivered radioisotope so as to minimize 
irradiation of normal organs. In this way, by the time accu-
mulation of the radiolabeled carrier at normal organs starts International Journal of Nanomedicine 2008:3(2) 193
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to become signiﬁ  cant, the therapeutic radionuclide can be 
chosen so as to have mostly decayed. However, in order 
to achieve therapeutic effects the drug delivery carriers are 
required to exhibit sustained retention in the peritoneal cav-
ity increasing the probability of encountering tumor sites. 
Relatively large delivery carriers such as microspheres and 
liposomes are promising in this sense as they show slow 
clearance from the peritoneal cavity (Delgado et al 1989; 
Verschraegen et al 2003).
In peritoneal carcinomatosis, traditional therapeutic pro-
cedures may involve peritoneal surgical debulking followed 
by systemic administration of chemotherapeutics and radia-
tion. Direct intraperitoneal administration has been studied 
and appears promising against minimal residual disease but 
not bulky disease (Epenetos et al 1987; Crippa et al 1995; 
Meredith et al 1996). Alpha particle emitters due to their 
short range in tissues matching the dimensions of micro-
metastatic disease could be a logical choice (Meredith et al 
1996; Borchardt et al 2003; Palm et al 2007). The high LET 
of these emitters is advantageous for high killing efﬁ  cacy. 
Beta particle emitters would deposit high enough dose only 
to relatively larger tumors, and could potentially irradiate in 
signiﬁ  cant depth the surrounding healthy tissue.
For locoregional therapy in the peritoneum, several dif-
ferent carriers and targeting systems have been studied for 
the delivery of radionuclides. One of the ﬁ  rst published stud-
ies investigated the administration of micron-size colloids 
labeled with the alpha-emitter Astatine-211 (t1/2 = 7.21 hr, 
E = 6.8 MeV and 65 µm path length in tissue). Tellurium 
was chosen to form the colloid microspheres due to its strong 
afﬁ  nity for astatine. These studies showed curative effects 
that were dose depended without serious morbidity in mice 
with intraperitoneally disseminated murine ovarian carci-
noma. They also showed lower toxicity relative to studies 
where intravenous administration of comparable 211At doses 
were delivered, emphasizing in this way the importance of 
regional administration (Bloomer et al 1981).
A few characteristic examples of several radionuclide 
carriers and approaches are given below in more detail 
covering different strategies that range from radiolabeled 
monoclonal antibodies to dendrimers, protein complexes, 
polypeptides, and liposomes in direct (single step) or multi-
step (pretargeting) schemes.
Borchardt and colleagues (2003) compared the intraperi-
toneal and intravenous administration of an anti-HER2/neu 
antibody – trastuzumab- labeled with the alpha particle gener-
ator Actinium-225 (t1/2 = 10 days, four emitted alpha particles 
per parent decay) in mice bearing peritoneally disseminated 
ovarian carcinoma that resembled micrometastatic disease. 
The study showed signiﬁ  cantly enhanced tumor localization 
of the radionuclides when administered intraperitoneally 
without increase of normal organ toxicities compared to 
the intravenous route. To reduce toxicities to normal organs 
due to released radioactive daughters from the raioimmu-
noconjugates addition of compounds for faster clearance of 
radio-toxins have been proposed (Jaggi et al 2005).
Another approach for the reduction of toxicities to normal 
organs is to decrease the loss of radioactive daughters from 
the  225Ac carrier by developing large multivesicular anti-
HER2/neu-liposomes. These are large 650 nm in diameter 
liposomes encapsulating smaller lipid vesicles that contain 
the parent radionuclide. They are proposed for locoregional 
therapy of peritoneally disseminated ovarian cancer micro-
metastases. These liposomes are shown to exhibit reten-
tion of 20% of 123Bi – the last alpha emitting radioactive 
daughter – due to their internal structure. This translates 
into control of 2.6 out of 4 alpha particles that are generated 
per 225Ac. These anti-HER2/neu-liposomes were shown to 
exhibit speciﬁ  c binding and internalization by cancer cells in 
vitro (Sofou et al 2007). At the tumors, in vivo, the delivered 
activities of 225Ac by liposomes were comparable to those 
delivered by radiolabeled antibodies twenty four hours after 
intraperitoneal administration, and showed higher daugh-
ter-to-parent ratios compared to the ratios exhibited when 
antibodies were administered (Sofou et al 2004a).
For the therapy of intraperitoneally disseminated tumors, 
dendrimers have been studied as delivery carriers for Auger 
emitters to improve the radionuclide load that is required 
for therapeutic applications. Multiple chelating agents were 
attached to biotinylated dendrimers that were mixed with avi-
din to form larger complexes. Intraperitoneal administration 
of dendrimer complexes with high 111In speciﬁ  c activities was 
performed on animals bearing intraperitoneal disseminated 
ovarian cancer tumors (Mamede et al 2003). The cationic 
charge of the fourth generation dendrimers forming the 
complexes, combined with the reported ability of avidin to 
enhance tumor accumulation, resulted in enhanced binding 
and internalization of the complexes by ovarian carcinoma 
cells with high tumor accumulation in vivo. In treatment 
studies, these high dose complexes showed tolerable and 
dose-depended therapeutic effects.
Multistep or pretargeting approaches have been explored 
in intraperitoneal radiotherapy but not as extensively as in 
intravenous RIT (vide infra). For maximum killing efﬁ  cacy 
and minimized toxicities, pretargeting strategies aim to 
decouple the pharmacokinetics of targeting ligands – that may International Journal of Nanomedicine 2008:3(2) 194
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be characterized by slow tumor uptake, small binding frac-
tion to tumors, or slow clearance from normal organs—from 
the potentially different kinetics required for the therapeutic 
radionuclides. Brieﬂ  y, at the ﬁ  rst step, a tumor-targeting 
molecule such as an antibody is administered. This targeting 
molecule should have high afﬁ  nity for cancer cells, is not 
radiolabeled, and also bears a second functionality that serves 
as a linker for the targeting in the following second step. Only 
after the ﬁ  st unlabeled bifunctional antibody is adequately 
cleared from the body but not from the tumor sites, a radio-
labeled “effector” compound is administered. The effector 
compound is designed to bind with very high avidity to the 
second functionality of the bifunctional antibody of the ﬁ  rst 
targeting step. The radiolabeled effector compound should 
have faster pharmacokinetics to clear rapidly from circula-
tion and the body, and could potentially also exhibit better 
permeation in the tumor.
To target 211At to intraperitoneal tumors, Lindegren and 
colleagues (2003) used a pretargeting compound containing 
avidin as the second functionality. At the second step, the 
effector molecule polylysine was introduced in a biotinylated 
form and was used as a multicarrier for 211At. The rationale 
for this approach is the potentially high speciﬁ  c radioactivity 
of polylysine that would enable delivery of high radiation 
doses for therapy. Biotinylated polylysines of various sizes 
exhibited strong binding to avidin-coated beads. Following 
intraperitoneal administration of the effector molecule, it was 
found that increasing molecular weights shifted the normal 
organ accumulation from the kidneys to the liver. Increased 
uptake at the thyroid, lungs, stomach, and the spleen was 
detected following administration of effector molecules 
(38 and 363 kDa) (Lindegren et al 2002). The authors suggest 
that this is caused by possible degradation of the polymers 
by the liver resulting in release of the radionuclide as free 
astatine/astatide. Addressing the issue of liver accumula-
tion and radiolabel release would signiﬁ  cantly advance this 
promising approach.
Beta emitters with short range in tissue such as 177Lu 
(t1/2 = 6.61 days, Emax = 497 keV for beta emissions) have 
been proposed as alternatives for targeting intraperitoneal 
carcinomatosis. Lutetium-177 emits beta particles with 
average penetration in soft tissues ranging from 0.2 to 0.3 
mm. Two beta particle emitters, 90Y and 177Lu, were studied 
and compared in a pretargeting approach for intraperito-
neal therapy. Yttium-90’s emitted beta particles travel as 
far as 2.76 mm in tissue. Lutitium-177 in addition to beta 
particles emits low energy gamma radiation of 113 and 208 
keV allowing for gamma camera imaging. In this study, 
a tetrameric fusion protein composed of CC49-scFv-chains 
on streptavidin was initially administered intraperitoneally 
to mice bearing peritoneal TAG-71-positive LS174T tumors. 
The CC49 protein was chosen based on its good tumor uptake 
and on evidence of no localization to normal gastrointestinal 
tissues. To reduce bone marrow suppression, the blood circu-
lating non bound fusion protein was cleared from circulation 
by intravenous administration of a synthetic clearing agent 
having high afﬁ  nity for hepatocytes for rapid removal from 
the blood, and fast internalization and catabolism by the 
liver cells. Then radionuclide-DOTA-biotin was adminis-
tered intraperitoneally. In therapeutic studies, the effector 
compound 177Lu-DOTA-biotin produced prolonged survival 
and appeared to be less toxic than 90Y-DOTA-biotin. At the 
maximum dose tested of 800 µCi, 60% of deaths were early 
deaths due to toxicity of 90Y-DOTA-biotin. No evidence of 
toxicity was observed for 177Lu-DOTA-biotin at the same 
dose. This result was attributed to the shorter recoil range of 
the 177Lu emitted beta particles (Buchsbaum et al 2005b).
Radioimmunotherapy
In Radioimmunotherapy (RIT), tumor-targeting antibodies 
are utilized for the delivery of therapeutic radionuclides. 
RIT is emerging as a very promising therapeutic modality, 
and progressively gains more ground compared with tradi-
tional chemotherapy. Although treatment of solid tumors 
is still a challenge for RIT mainly due to limited tumor cell 
accessibility by circulating antibodies (Jhanwar and Divgi 
2005; Sharkey and Goldenberg 2005), RIT has been success-
ful with small volume disease or minimal residual disease 
particularly with hematopoietic neoplasms (Sharkey and 
Goldenberg 2005). The two main components in RIT are the 
type of antibody used and the therapeutic radionuclides. For 
a systematic analysis of the existing approaches the readers 
are referred to reviews by Goldenberg (Goldenberg 2002) and 
Sgouros (Sgouros 2002). Although most RIT trials and com-
mercial radioimmunoconstructs involve beta particle emitters, 
clinical RIT trials with alpha particle emitters on small volume 
disease have demonstrated safety, feasibility and activity 
against cancer cells (Mulford et al 2005), and more alpha 
particle emitting isotopes are increasingly studied.
Single-step RIT
In single-step RIT, an initial major challenge was the unde-
sirable immunogenicity of the administrated antibodies 
that could prevent repeated therapeutic cycles. Advances in 
antibody engineering have been employed to provide anti-
bodies with decreased immunogenic responses and antibody International Journal of Nanomedicine 2008:3(2) 195
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fragments. However, smaller radioimmunoconjugates exhibit 
different biodistributions that essentially shift toxicities 
to other organs. As the antibody size decreases, toxicities 
shift from the bone marrow and the liver to the kidneys. In 
addition, the tumor binding uptake and retention of smaller 
fragments are decreased compared to the complete IgG’s. The 
different kinetic proﬁ  les of smaller radioimmunoconjugates 
can be successfully addressed by choosing radionuclides 
with matching half-lives, but the lower tumor accumulation 
observed for smaller antibody fragments may require higher 
administered doses to achieve lethal absorbed doses at the 
targeted cancer cells. This could proportionally increase 
toxicity at critical organs (Goldenberg 2002).
Multistep targeting
Multistep targeting is proposed as an alternative to combine 
reduced toxicities at normal organs with increased tumor-
to-normal organ ratios, and eventually deliver higher doses of 
radiation at the tumor. Numerous constructs, including mono- 
and bi-functional compounds and radionuclide combinations 
have been designed and evaluated. For extensive overviews 
on preclinical and clinical studies on RIT the readers are 
referred to other reviews speciﬁ  c on antibody pretargeting for 
radioimmunotherapy (Bethge and Sandmaier 2005; Koppe 
et al 2005; Sharkey and Goldenberg 2005; Goldenberg et al 
2006; Pohlman et al 2006).
The radiolabeling efﬁ  ciency – speciﬁ  c activity – of the 
construct that is used at the ﬁ  nal targeting step plays a deter-
mining role on the delivered radiation dose at the tumor. 
Several carriers other than antibodies, such as polypeptides 
and dendrimers that can be heavily radiolabeled, have been 
studied to improve the efﬁ  cacy of this ﬁ  nal step. However, 
the accumulation of these constructs to normal organs usually 
renders these approaches questionable for effective therapy 
(del Rosario and Wahl 1993; Wilbur et al 1998). For example, 
starburst PAMAM polyamidoamine dendrimers have been 
reported for the targeted delivery of 111In and 88Y (t1/2 = 106.65 
days, beta emissions with Emax = 0.76 MeV, gamma pho-
tons of E = 1.83 MeV). Second generation dendrimers are 
highly branched and are proposed as alternative chelating 
platforms for the attachment of radionuclides (Kobayashi 
et al 1999). However, the positively charged dendrimers 
seem to extensively accumulate in the liver, spleen, and the 
pancreas. Alternative approaches to address this toxicity 
issue are necessary.
A different approach to multistep targeting is MitraDep® 
that aims to decrease toxicity at normal organs while main-
taining high administered radiation doses for high tumor 
delivered doses. This approach involves the direct clearing 
of the circulating radiolabeled antibodies from the blood by 
extracorporeal depletion at the time point when their tumor 
localization becomes adequate and before the accumulation 
in normal organs becomes signiﬁ  cant. This is achieved by 
passing the entire blood ﬂ  ow through a ﬁ  lter coated with 
avidin to remove the radiolabeled antibodies that have 
been simultaneously biotinylated. The antibody’s func-
tionalization takes place through the trifunctional chelator 
[3-(13’-thioureabenzyl-DOTA)trioxadiamine-1-(13’’-bio-
tin-Asp-OH)trioxadiamine-5-isothiocyanato-aminoisophta-
late] to ensure the ratio of biotin-to-DOTA is 1:1. Otherwise, 
the radiolabeled antibodies that are not biotinylated would 
not be cleared using extracorporeal depletion. The reported 
phase I study, shows that this procedure is safe in the sense 
that it does not expose the patients to risks such as blood 
coagulation, perturbation of hematological parameters, 
activation of the immunological system or decrease of elec-
trolytes in the blood. In addition, for 111In labeled rituximab 
that was used as 90Y surrogate, 62% depletion of activity 
was detected in the lungs, and 40% in the liver and kidneys. 
This device is currently on a dose-escalating phase I/II study 
(Linden et al 2005).
Preactivated RIT
As mentioned above, RIT is not as effective for solid tumors 
as for easily accessible disease. This is because RIT is 
usually designed to target accessible molecular markers on 
the surface of tumor cells. For solid tumors, on the contrary, 
the radioimmuno-constructs need to ﬁ  rst extravasate into the 
tumor interstitium before reaching the tumor cells. Thus, 
issues related to poor tumor penetration, or low tumor antigen 
and receptor expression may present signiﬁ  cant challenges. 
To enhance targeting to molecular markers on tumor cells, 
upregulation of tumor-related antigens and receptors has 
been proposed using viral vectors or by the administration 
of cytokines (Rogers et al 2002).
A very interesting example is the upregulation of the 
somatostatin receptor SSTr2 on the surface of human non-
small cell lung tumor xenografts before administration of a 
therapeutic radiolabeled antibody. Following intratumoral 
administration of an adenovirus encoding the SSTr2 gene, 
the authors showed that high levels of the somatostatin 
receptor SSTr2 were induced on the surface of cancer cells. 
Then, following intravenous administration, these cancer 
cells were targeted by an ostreotide analogue labeled with 
the beta-emitter 90Y (Rogers et al 2002). This study showed 
that upregulation of the targeting receptors on the surface International Journal of Nanomedicine 2008:3(2) 196
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of cancer cells comprising the solid tumors is possible to 
achieve therapeutic efﬁ  cacy by radiolabeled antibodies with 
beta emitters that otherwise is not achievable. Somatostatin 
receptors have also been studied on ovarian cancer xenografts 
(Rogers et al 1999), and have been upregulated by ionizing 
radiation (Buchsbaum et al 2005a). The curative potential of 
90Y-based radiotherapy targeted to somatostatin expressing 
tumors has been shown in several studies (Stolz et al 1998; 
de Jong et al 2001). The approach of preactivation could 
provide a feasible answer to the radioimmunotherapy of solid 
tumors. Hopefully, current limitations in adenoviral vectors 
due to high liver toxicities would be eventually surpassed 
leading to a new direction for RIT.
Conclusions
In internal radiotherapy of cancer, a variety of diverse 
parameters characterizing the tumor topology, morphol-
ogy, and physiology need to be considered for choosing 
the optimal targeting ligand, delivery carrier, and type of 
therapeutic radionuclide for effective therapy. In addition, 
the stability of constructs, and the fate of free radionu-
clides in vivo play a signiﬁ  cant role on the success of the 
therapeutic strategy. These factors result in the design of 
different materials and constructs that are brieﬂ  y summa-
rized in this review.
Currently, clinical trials on targeted radionuclide thera-
pies are mostly based on small molecules both for targeting 
and delivery that include antibodies, smaller peptides (Wong 
2006; Dearling and Pedley 2007), or the radiolabeled biotin/
avidin pair (Paganelli et al 2007). Advancement in the area 
of internal radionuclide therapy may further be enabled by 
using different carrier materials with higher radionuclide 
loads exhibiting different behavior in vivo such as liposomes, 
dendrimers, and other structures with sizes of the order of 
several nanometers. Better understanding of the interactions 
of new constructs with the biological milieu, proof of the 
safety of new constructs, improvements in radiochemistry for 
stable and efﬁ  cient radiolabeling, progress in antibody and 
other ligand engineering and wide availability of a variety of 
radionuclides, should enable internal radiotherapy to reach 
its full potential.
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